Endocrinological side-effects of immune checkpoint inhibitors

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 278-287

  Torino, Francesco ^a   Corsello, Salvatore M ^b   Salvatori, Roberto ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

anticytotoxic T lymphocyte associated protein 4; antiprogrammed death protein 1; antiprogrammed death ligand 1; immune checkpoint inhibitors; immunotherapy; ipilimumab; nivolumab; pembrolizumab

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; IMMUNE CHECKPOINT INHIBITOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADRENAL DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; ENDOCRINE DISEASE; HUMAN; HYPOPHYSITIS; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THYROID DISEASE; ANIMAL; CHEMICALLY INDUCED; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENDOCRINE SYSTEM DISEASES; HUMANS; NEOPLASMS;

EID: 84964761784     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000293     Document Type: Review

References (76)

1. Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49:907-937.
2. Abdel-Rahman O, El Halawani H, FouadM. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol 2016; 12:413-425.
3. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33:3193-3198.
4. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21:371-381.
5. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21:749-755.
6. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99:4078-4085.
7. Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumabinduced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015; 172:195-204.
8. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.
9. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
11. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
12. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall-cell lung cancer: results from a randomized, double-blind, multicentre phase II study. J Clin Oncol 2012; 30:2046-2054.
13. Hamid O, Hwu WJ, Richards JM, et al. Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. J Clin Oncol 2012; 30:8508.
14. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16:1042-1048.
15. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-622.
16. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
17. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33:1430-1437.
18. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (antiprogrammed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced nonsmall-cell lung cancer. J Clin Oncol 2015; 33:2004-2012.
19. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmall-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-265.
20. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
21. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med 2015; 373:123-135.
22. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
23. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
24. Robert C, Ribas A, Wolchok JD, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-1117.
25. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908-918.
26. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-2532.
27. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall cell lung cancer. N Engl J Med 2015; 372:2018-2028.
28. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015. S0140-6736(15)01281-7 doi: 10. 1016/S0140-6736(15)01281-7.
29. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
30. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
31. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
32. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
33. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014; 32:55.
34. Rizvi NA, Brahmer JR, Ou SI, et al. Safety and clinical activity of MEDI4736, an antiprogrammed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 2015; 33:155.
35. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factortransduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-517.
36. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12:116.
37. http://packageinserts. bms. com/pi/pi-yervoy. pdf [Accessed on 25 January 2016]
38. Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011; 29:8511.
39. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-642.
40. Haanen JB, van Thienen HV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 2015; 42:423-428.
41. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
42. Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33:2092-2099.
43. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-2391.
44. http://packageinserts. bms. com/pi/pi-opdivo. pdf [Accessed on 25 January 2016]
45. Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21:712-720.
46. http://www. merck. com/product/usa/pi-circulars/k/keytruda/keytruda-pi. pdf. [Accessed on 25 January 2016]
47. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 2014; 20:6258-6268.
48. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98:1361-1375.
49. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-598.
50. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:499-507.
51. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-830.
52. Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29-38.
53. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocrine Rev 2005; 26:599-614.
54. Faje AT, Sullivan R, Lawrence D, et al. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19:82-92.
55. Juszczak A, Gupta A, Karavitaki N, et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 2012; 167:1-5.
56. Barnard ZR, Walcott BP, Kahle KT, et al. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol 2012; 29:374-377.
57. Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 2012; 18:351-355.
58. YERVO (ipilimumab) US Prescribing Information: risk evaluation and mitigation strategy (REMS). Princeton, NJ, USA: Bristol-Myers Squibb Company, 2011. Available online: https://www. hcp. yervoy. com/pages/rems. aspx. [Accessed January 2016]
59. Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010; 37:440-449.
60. Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015; 1:433-440.
61. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4:560-575.
62. Weber JS, Kä hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697.
63. Weber JS, Dummer R, de Pril V, et al., MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-1682.
64. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014; 6:230-245.
65. Laurent S, Queirolo P, Boero S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J Transl Med 2013; 11:108.
66. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cellmediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015; 112:6140-6145.
67. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5:520.
68. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164:303-307.
69. Borodic G, Hinkle DM, Cia Y. Drug-induced Graves' disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011; 27: e87-e88.
70. Torino F, Barnabei A, Paragliola R, et al. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 2013; 23:1345-1366.
71. Di Giacomo AM, Ascierto PA, Queirolo P, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26:798-803.
72. Di Giacomo AM, Danielli R, Calabrò L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467-477.
73. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29:455-463.
74. Corsello SM, Salvatori R, Barnabei A, et al. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol 2013; 72:489-490.
75. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559-574.
76. Rossi E, Sgambato A, Chiara G, et al. Endocrinopathies induced by immunecheckpoint inhibitors in advanced nonsmall cell lung cancer. Expert Rev Clin Pharmacol 2016; 9:419-428.